Search Results - "Galea, Celine"
-
1
Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors
Published in Cancer Immunology, Immunotherapy (01-10-2010)“…Purpose Vγ9Vδ2 (γδ) T lymphocytes, a critical peripheral blood lymphocyte subset, are directly cytotoxic against many solid and hematologic tumor types. Vγ9Vδ2…”
Get full text
Journal Article -
2
Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vg9Vd2 T lymphocyte agonist in patients with solid tumors
Published in Cancer Immunology, Immunotherapy (01-10-2010)“…Purpose: Vg9Vd2 (gd) T lymphocytes, a critical peripheral blood lymphocyte subset, are directly cytotoxic against many solid and hematologic tumor types…”
Get full text
Journal Article -
3
Phase-I study of Innacell gamma delta registered , an autologous cell-therapy product highly enriched in gamma 9 delta 2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
Published in Cancer Immunology, Immunotherapy (01-11-2008)“…Purpose: gamma 9 delta 2 T lymphocytes have been shown to be directly cytotoxic against renal carcinoma cells. Lymphocytes T gamma delta can be selectively…”
Get full text
Journal Article -
4
-
5
Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
Published in Cancer Immunology, Immunotherapy (01-11-2008)“…Purpose γ9δ2 T lymphocytes have been shown to be directly cytotoxic against renal carcinoma cells. Lymphocytes T γδ can be selectively expanded in vivo with…”
Get full text
Journal Article -
6
Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V[gamma]9V[delta]2 T lymphocyte agonist in patients with solid tumors
Published in Cancer immunology, immunotherapy (01-10-2010)“…Vγ9Vδ2 (γδ) T lymphocytes, a critical peripheral blood lymphocyte subset, are directly cytotoxic against many solid and hematologic tumor types. Vγ9Vδ2 T…”
Get full text
Journal Article -
7
Phase-I study of Innacell [gamma][Delta](TM), an autologous cell-therapy product highly enriched in [gamma]9[Delta]2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
Published in Cancer immunology, immunotherapy (01-11-2008)“…[gamma]9[Delta]2 T lymphocytes have been shown to be directly cytotoxic against renal carcinoma cells. Lymphocytes T [gamma][Delta] can be selectively expanded…”
Get full text
Journal Article -
8
Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
Published in Cancer immunology, immunotherapy : CII (01-11-2008)“…gamma9delta2 T lymphocytes have been shown to be directly cytotoxic against renal carcinoma cells. Lymphocytes T gammadelta can be selectively expanded in vivo…”
Get full text
Journal Article -
9
Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors
Published in Cancer immunology, immunotherapy (01-10-2010)“…Vgamma9Vdelta2 (gammadelta) T lymphocytes, a critical peripheral blood lymphocyte subset, are directly cytotoxic against many solid and hematologic tumor…”
Get full text
Journal Article